TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07477743: Phase Ib Study to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of HC010 Combinations in Patients With Advanced Solid Tumors and Determine the Recommended Dose for Subsequent Studies.

Sponsor: HC Biopharma Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 331 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07477743 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07477743 Rescue Dossier →